Targeting osteosarcoma, a cancer more common in young people

Knight Cancer researchers describe positive results with the drug regorafenib. Osteosarcoma is a bone cancer that disproportionately affects teenagers, and despite substantial efforts, outcomes for...

Halting resurgent prostate cancers before they spread

Q&A: Prostate cancer expert Julie Graff, M.D., explains how a new treatment option fills a void for men with resurgent tumors. When prostate cancer isn't cured by surgery or radiation, the...

Intel pledges crowdfunding for precision oncology at OHSU

A precision oncology clinical trial in the works at the OHSU Knight Cancer Institute gained a $25,000 pledge from Intel Corp. The company said it will contribute the money by means of a fund...

Immunotherapy takes a new turn for life-threatening prostate cancer

At the recent European Society for Medical Oncology meeting, OHSU oncologist Julie Graff, M.D., presented the first evidence of meaningful clinical activity for PD-1 blockade in men with...